Work

Abstract 2679: Integration of DNA repair deficiency and immune biomarkers to predict which early-stage triple-negative breast cancer patients are likely to respond to platinum-containing regimens vs. immunotherapy: The neoadjuvant I-SPY 2 trial

Year: 2019

Type: conference-abstract

Source: Clinical Research (Excluding Clinical Trials)

DOI: 10.1158/1538-7445.sabcs18-2679

Authors: Denise M. Wolf, Christina Yau, Julia Wulfkuhle, Emanuel Petricoin, Lamorna Brown-Swigart, Gillian Hirst, Smita Asare, Douglas Yee, Angela DeMichele, Hope Rugo, Olufunmilayo Olopade, Rita Nanda, Minetta Liu, Laura Esserman, Laura van t' Veer

Institutions: University of California, San Francisco, George Mason University, Quantum Leap Healthcare Collaborative, University of Minnesota, University of Pennsylvania, University of Chicago, Mayo Clinic

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4252103618

Cites:

Cited by:

Related to: 10